Abbott Laboratories

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell

AI-generated analysis

📉 Okta shares have fallen nearly 40% from their 52-week high due to AI fears regarding cybersecurity relevance.

🤝 Director David Schellhase bought $267,000 worth of Okta stock in Q2 under a prearranged 10b5-1 plan.

⚖️ While total insider sales at Okta reached $1.2 million, the buys are considered bullish because they signal conviction.

📈 Micron shares have gained over 240% in 2025 and more than 170% in 2026 due to AI data center demand.

🚀 The company reported record revenue of $23.9 billion (up 196%) and EPS of $12.20 (up 682%) last quarter.

💸 Insider selling at Micron increased to $45 million in Q2, driven largely by $35 million in pre-planned 10b5-1 transactions.

🔨 CEO Sumit Sadana sold $10.1 million of shares, representing only a 10% trim of his holdings rather than a full exit.

🩺 Abbott Laboratories stock is down over 30% in 2026 following mixed earnings and lowered guidance.

💰 Total insider buying at Abbott reached $1.13 million in Q2 with zero insider sales recorded that quarter.

🎯 Wall Street analysts maintain a consensus price target of approximately $119, implying more than 40% upside.

⚠️ The article notes that insider trades are just one indicator and should not be viewed as standalone declarations of future stock performance.

📊 Okta's mixed insider activity contrasts with the clear bullish signal from directors buying despite AI-related headwinds.

Bullish Signals
  • Okta director David Schellhase purchased approximately $267,000 worth of stock in Q2 under a predetermined 10b5-1 plan, signaling sustained conviction that the price will rise.
  • Insider buys at Okta are potentially more bullish than non-plan purchases because they indicate confidence in future price appreciation even amidst significant market volatility.
  • Micron has achieved record financial metrics with revenue rising by an astonishing 196% year-over-year to $23.9 billion and earnings per share surging by 682% YOY to $12.20.
  • The majority ($35 million) of Micron's insider sales came under a 10b5-1 plan used for liquidity rather than negative sentiment, while Sumit Sadana's sale represented only a moderate trim of roughly 10% of his holdings.
  • Abbott Laboratories insiders have executed consecutive quarters of buying in Q2 (totaling $1.13 million) and Q1 ($1.09 million), while tracking zero sales in Q2 so far.
  • Multiple insiders are buying Abbott shares at a discount, having purchased during the stock's significant decline of over 30% in 2026, indicating they view the current price as an attractive entry point.
  • Wall Street analysts confirm the bullish insider sentiment on Abbott with a consensus price target near $119, implying more than 40% upside potential from current levels.
Risk Factors
  • Okta (OKTA) shares have struggled considerably, trading down almost 40% from their 52-week high due to fears that artificial intelligence will solve cybersecurity problems and reduce the need for such companies.
  • Okta insider sales in Q2 outweighed purchases by $933,000 ($1.2 million in sales versus $267,000 in buys), indicating potential distribution despite some planned purchases under 10b5-1 plans.
  • Abbott Laboratories (ABT) shares have declined over 20% since the start of 2025 and more than 30% in 2026 as markets reacted negatively to missed revenue expectations and lowered guidance.
  • Abbott's Q4 2025 revenue fell below expectations by $342 million, while its full-year EPS guidance was lowered following a mixed earnings report that contributed significantly to the stock's decline.
  • Micron insider sales increased approximately 106% quarter-over-quarter in Q2 to $45 million compared to $22 million last quarter, driven largely by Sumit Sadana's $10.1 million sale and other planned sales totaling $35 million.
Full Analysis
Abbott Laboratories (NYSE: ABT) insiders have demonstrated significant bullish sentiment as the healthcare equipment giant continues to face a steep decline in 2026. Following mixed fourth-quarter results where revenue missed expectations by $342 million and subsequent Q1 2026 earnings that forced a full-year guidance lower, Abbott shares have fallen over 20% since early 2025 and more than 30% throughout 2026 specifically. Despite this volatility, Q2 activity shows no insider sales totaling $1.13 million in purchases, which builds upon $1.09 million in buys from the previous quarter. This consistent buying pattern suggests insiders view the current price as an attractive entry point for long-term growth potential. Wall Street analysts corroborate this optimism, with consensus price targets near $119 implying over 40% upside from current levels, reinforcing the positive signal sent by internal transactions despite recent earnings-driven volatility. In contrast to the strong insider buying at Abbott, Micron Technology (NASDAQ: MU) is witnessing increased insider selling as it rides a massive stock rally driven by AI demand. Following a staggering 240% gain in 2025 and an additional 170% rise in early 2026, Micron insiders sold approximately $45 million worth of shares in Q2, doubling the sales volume from $22 million in the prior quarter. However, much of this selling occurred under pre-planned 10b5-1 liquidity arrangements, meaning only a portion represents active liquidation, including a moderate trim by executive Sumit Sadana that accounted for roughly 10% of his holdings rather than an exit. Analysts view these sales as non-critical given the company's record-breaking performance, which includes revenue soaring 196% year-over-year to $23.9 billion and earnings per share jumping 682% to $12.20 in its latest quarter, though the lack of any insider buys compared to $7.8 million in Q1 does present a neutral-to-negative signal. Finally, Okta (NASDAQ: OKTA) presents a mixed picture where one insider's confidence stands out against a backdrop of broader market weakness and artificial intelligence fears. The cybersecurity leader is down nearly 40% from its 52-week high as investors worry AI models might render traditional identity management less critical. Despite heavy insider selling of $1.2 million in Q2, Director David Schellhase executed a purchase worth approximately $267,000 within the same period. Both the buy and the subsequent sales were executed under 10b5-1 plans designed for long-term liquidity management rather than immediate trading signals, but market analysts generally interpret any insider buying as a stronger bullish indicator because it suggests conviction that the stock price will rise in the future.